Selected References

Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011 Oct 30;17(11):1498-503 Abstract

Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes.Nat Rev Cancer. 2011 Sep 23;11(10):719-25. Abstract

Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag A, Im HK, Jagadeeswaran S, Shaw DE, Mazar AP, Lengyel E. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res. 2011 Feb 1;17(3):459-71. Epub 2010 Dec 13. PubMed PMID: 21149615; PubMed Central PMCID: PMC3073583 Abstract

Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K, Lengyel E. Ligand-independent activation of c-Met by fibronectin and α(5)β(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene. 2011 Mar 31;30(13):1566-76. Epub 2010 Nov 29. PubMed PMID: 21119598; PubMed Central PMCID: PMC3069218. Abstract

Lengyel, E. Ovarian Cancer Development and Metastasis. Am J Pathol. 2010 Sept;177(3):1053-64 Abstract

Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E, Peter ME. CD95 promotes tumour growth. Nature. 2010; 465:492-6 Abstract

Zillhardt M, Christensen JG, Lengyel E., An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia. 2010, 12:1-10. Full text

Ko SY, Lengyel E, Naora H.The Müllerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelial-stromal interactions.Mol Cell Endocrinol. 2010, 317(1-2)::112-9.Abstract

Kenny HA, Lengyel E. MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle 2009;8:683-8.Abstract

Romero I, Gordon I, Jagadeeswaran S, Mui KL, Lee WS, Dinulescu D, Krausz T, Kim H, Gilliam M, Lengyel E. Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prevention Research 2009;2:792-9.Full text

Kenny HA, Dogan S, Zillhardt M, Mitra AB, Yamada SD, Krausz T, et al. Organotypic models of metastasis: A three dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. In: Stack MS, Fishman DA, editors. Ovarian Cancer. II ed. New York: Springer; 2009. p. 335-51.

Kenny HA, Kaur S, Coussens L, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 2008;118:1367-79. Full text

Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner E, Tretiakova MS, Jagadeeswaran S, Montag A, Becker A, Kenny HA, Peter ME, Ramakrishnan V, Yamada SD, Lengyel E. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res 2008;68:2329-39.Abstract

Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressor ZEB1 and ZEB2. Genes Dev 2008;22:894-907. Full text

Kenny HA, Krausz T, Yamada SD, Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells. Int J Cancer 2007;121:1463-72.Abstract

Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu D, Lengyel E, Peter ME. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 2007;6:1-6.Abstract

Shell S, Park SM, Radjabi AR, Schickel R, Kistner E, Jewell DA, Feig C, Lengyel E, Peter ME. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 2007;104:11400-5. Abstract

Lengyel E, Sawada K, Salgia R. Tyrosine kinase mutations in human cancer. Current Molecular Medicine 2007;7:77-84.Abstract

Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny HA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E. C-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007;67:1670-80. Full text

Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen BS, Vande Woude GF, Harbeck N. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/Neu. Int J Cancer 2005;113:678-82. Abstract

Kugler M, Gerhard M, Schnelzer A, Borzym K, Reinhardt R, Schmitt M, Lengyel E. Isolation and characterization of Rac1 pseudogenes (y1Rac1-y4Rac1) in the human genome. Gene 2004;341:189-97 Abstract

Besta F, Massberg S, Brand K, Mueller B, Page S, Grüner S, Lorenz M, Sadoul K, Kolanus W, Lengyel E, Gawaz M. Role of b3-endonexin in the regulation of NF-kB dependent expression of urokinase-type plasminogen activator receptor. J Cell Science 2002;115:3879-88. Full text

Hapke S, Gawaz M, Dehne K, Köhler J, Marshall JF, Graeff H, Schmitt M, Reuning U, Lengyel E. b3A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter. Mol Cell Biol 2001;21:2118-32.Full text

Schmalfeldt B, Prechtel D, Haerting K, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001;7:2396-404. Abstract

Lengyel E, Schmalfeldt B, Konik E, Härting K, Fenn A, Fridman R, Schmitt M, Prechtel D, Kuhn W. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 2001;82:291-8. Abstract

Hannke-Lohmann A, Pildner von Steinburg S, Dehne K, Benard V, Kolben M, Schmitt M, Lengyel E. Downregulation of a mitogen-activated protein kinase signaling pathway in the placenta of patients with preeclampsia. Obstet Gynecol 2000;4:582-7.Abstract

Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, Harbeck N, Schmitt M, Lengyel E. Rac1 in human breast cancer: Overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 2000;19:3013-20.Full text

Lengyel E, Wang H, Gum R, Simon C, Wang Y, Boyd D. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular-signal regulated kinase 1 dependent signaling cascade. Oncogene 1997;14:2563-74. Full text

Lengyel E, Wang H, Stepp E, Juarez J, Wang Y, Doe WF, Pfarr CM, Boyd D. Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. J Biol Chem 1996;271:23176-84.Full text

Ried S, Jäger C, Jeffers M, Vande Woude GF, Graeff H, Schmitt M, Lengyel E. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor (HGF/SF). J Biol Chem 1999;274:16377-86.Full text

Schaller G, Fuchs I, Pritze W, Ebert A, Kratsch HC, Herbst H, Pantel K, Lengyel E. Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res 1996;2:1879-85.Full text

Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, Boyd D. Stimulation of 92-kDA gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem 1996;271:10672-80. Full text

Lengyel E, Gum R, Stepp E, Juarez J, Wang H, Boyd D. Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. J Cell Biochem 1996;61:430-8.Abstract

Lengyel E, Gum R, Juarez J, Clayman G, Seiki M, Sato H, Boyd D. Induction of Mr 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts. Cancer Res 1995;55:963-7.Full text

Lengyel E, Stepp E, Gum R, Boyd D. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J Biol Chem 1995;270:23007-12. Full text

Lengyel E, Klostergaard J, Boyd D. Stimulation of urokinase expression by TNF-a requires the activation of binding sites for the AP-1 and PEA3 transcription factors. Biochim Biophys Acta 1995;1268:65-72. Abstract

Lengyel E, Singh B, Gum R, Nerlov C, Sabichi A, Birrer MJ, Boyd D. Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene. Oncogene 1995;11:2639-48.Abstract